| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 13 | 2024 | 152 | 2.970 |
Why?
|
| B7-H1 Antigen | 18 | 2024 | 273 | 2.330 |
Why?
|
| Antibodies, Monoclonal, Humanized | 22 | 2024 | 967 | 2.140 |
Why?
|
| NF-kappa B | 11 | 2016 | 465 | 1.760 |
Why?
|
| T-Lymphocytes | 15 | 2016 | 1223 | 1.740 |
Why?
|
| Albumins | 7 | 2021 | 129 | 1.270 |
Why?
|
| Paclitaxel | 8 | 2021 | 479 | 1.180 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2008 | 200 | 1.180 |
Why?
|
| Graft Rejection | 10 | 2016 | 1064 | 0.980 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 540 | 0.910 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 459 | 0.870 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 195 | 0.850 |
Why?
|
| CARD Signaling Adaptor Proteins | 4 | 2012 | 15 | 0.810 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 2552 | 0.810 |
Why?
|
| Antibodies, Monoclonal | 12 | 2019 | 1400 | 0.780 |
Why?
|
| Heart Transplantation | 6 | 2016 | 716 | 0.780 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2012 | 394 | 0.730 |
Why?
|
| Lymphocyte Activation | 11 | 2016 | 751 | 0.680 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 763 | 0.650 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2014 | 306 | 0.620 |
Why?
|
| Biomarkers, Tumor | 10 | 2024 | 1543 | 0.580 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 2411 | 0.560 |
Why?
|
| Cell Differentiation | 2 | 2012 | 1521 | 0.510 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 117 | 0.510 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1975 | 0.490 |
Why?
|
| Interleukin-7 | 1 | 2014 | 41 | 0.470 |
Why?
|
| Skin Transplantation | 3 | 2016 | 183 | 0.460 |
Why?
|
| Melanoma | 3 | 2019 | 467 | 0.460 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2014 | 42 | 0.460 |
Why?
|
| Bevacizumab | 4 | 2024 | 287 | 0.460 |
Why?
|
| Signal Transduction | 9 | 2016 | 3373 | 0.450 |
Why?
|
| Mice, Inbred BALB C | 10 | 2016 | 1087 | 0.440 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 3209 | 0.440 |
Why?
|
| Th17 Cells | 2 | 2014 | 84 | 0.430 |
Why?
|
| Genetic Variation | 1 | 2019 | 1371 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1363 | 0.420 |
Why?
|
| Transplantation | 1 | 2012 | 38 | 0.410 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 171 | 0.400 |
Why?
|
| Dendritic Cells | 2 | 2012 | 442 | 0.400 |
Why?
|
| Mice | 20 | 2023 | 11737 | 0.390 |
Why?
|
| Killer Cells, Natural | 3 | 2008 | 275 | 0.390 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 82 | 0.390 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 313 | 0.360 |
Why?
|
| Galectin 1 | 2 | 2011 | 6 | 0.350 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2016 | 215 | 0.350 |
Why?
|
| Female | 30 | 2024 | 46011 | 0.340 |
Why?
|
| Humans | 48 | 2024 | 89063 | 0.340 |
Why?
|
| Transplantation, Homologous | 8 | 2016 | 995 | 0.340 |
Why?
|
| Middle Aged | 23 | 2024 | 25863 | 0.340 |
Why?
|
| Obesity | 1 | 2016 | 966 | 0.330 |
Why?
|
| Indoles | 2 | 2024 | 312 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 1114 | 0.330 |
Why?
|
| Mice, Transgenic | 6 | 2016 | 1574 | 0.330 |
Why?
|
| CD28 Antigens | 4 | 2011 | 90 | 0.330 |
Why?
|
| Caspases | 1 | 2009 | 155 | 0.330 |
Why?
|
| fas Receptor | 1 | 2009 | 77 | 0.330 |
Why?
|
| Animals | 22 | 2023 | 27317 | 0.320 |
Why?
|
| Cytokines | 4 | 2019 | 802 | 0.320 |
Why?
|
| CD3 Complex | 3 | 2011 | 134 | 0.310 |
Why?
|
| Thymus Gland | 1 | 2009 | 197 | 0.310 |
Why?
|
| STAT5 Transcription Factor | 3 | 2014 | 43 | 0.310 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2004 | 125 | 0.300 |
Why?
|
| Skin | 3 | 2019 | 581 | 0.300 |
Why?
|
| Langerhans Cells | 1 | 2007 | 14 | 0.300 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 2 | 2004 | 34 | 0.300 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 46 | 0.300 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2004 | 39 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1265 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 373 | 0.300 |
Why?
|
| Cell Cycle | 1 | 2009 | 509 | 0.290 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 181 | 0.290 |
Why?
|
| Mice, Knockout | 6 | 2012 | 1990 | 0.280 |
Why?
|
| Isoantigens | 3 | 2012 | 70 | 0.280 |
Why?
|
| Up-Regulation | 3 | 2004 | 727 | 0.280 |
Why?
|
| I-kappa B Kinase | 3 | 2016 | 41 | 0.270 |
Why?
|
| Automation | 2 | 2024 | 111 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 2 | 2003 | 197 | 0.260 |
Why?
|
| Inflammation | 3 | 2016 | 971 | 0.250 |
Why?
|
| src-Family Kinases | 1 | 2004 | 76 | 0.240 |
Why?
|
| Adult | 21 | 2024 | 26507 | 0.240 |
Why?
|
| Aged | 18 | 2024 | 19077 | 0.230 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 2347 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 77 | 0.230 |
Why?
|
| Neoplasm Metastasis | 4 | 2021 | 1108 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 665 | 0.230 |
Why?
|
| Immunophenotyping | 1 | 2024 | 217 | 0.220 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2003 | 3 | 0.220 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3657 | 0.220 |
Why?
|
| Ovalbumin | 2 | 2014 | 109 | 0.210 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 98 | 0.200 |
Why?
|
| Interleukin-2 | 3 | 2011 | 251 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 285 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2023 | 261 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 295 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1796 | 0.190 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1714 | 0.190 |
Why?
|
| Kinetics | 3 | 2018 | 1528 | 0.190 |
Why?
|
| Immunotherapy | 5 | 2024 | 669 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 131 | 0.180 |
Why?
|
| Immunoassay | 1 | 2020 | 91 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 111 | 0.180 |
Why?
|
| Cells, Cultured | 6 | 2011 | 2880 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8203 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 443 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2020 | 42 | 0.170 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6777 | 0.170 |
Why?
|
| Reperfusion Injury | 2 | 2011 | 140 | 0.170 |
Why?
|
| Prognosis | 4 | 2020 | 3773 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 616 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 235 | 0.160 |
Why?
|
| Biomarkers | 3 | 2021 | 1755 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 103 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 281 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 421 | 0.160 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 781 | 0.160 |
Why?
|
| Graft Survival | 3 | 2016 | 898 | 0.150 |
Why?
|
| Interferon-gamma | 2 | 2016 | 451 | 0.150 |
Why?
|
| Isoenzymes | 2 | 2008 | 274 | 0.140 |
Why?
|
| Azetidines | 1 | 2017 | 37 | 0.140 |
Why?
|
| Apoptosis | 3 | 2011 | 1716 | 0.140 |
Why?
|
| Protein Kinase C | 2 | 2008 | 268 | 0.140 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 1940 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 395 | 0.140 |
Why?
|
| Neoplasms | 3 | 2024 | 3035 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2020 | 688 | 0.140 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 65 | 0.140 |
Why?
|
| Microfluidics | 1 | 2016 | 52 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 30 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2012 | 337 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 146 | 0.130 |
Why?
|
| Alleles | 1 | 2019 | 1135 | 0.130 |
Why?
|
| Piperidines | 1 | 2017 | 164 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2018 | 265 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1710 | 0.130 |
Why?
|
| Cell Survival | 3 | 2014 | 982 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2016 | 115 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2011 | 691 | 0.130 |
Why?
|
| Male | 12 | 2020 | 42251 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 245 | 0.120 |
Why?
|
| Spleen | 1 | 2016 | 432 | 0.120 |
Why?
|
| Quality of Life | 1 | 2023 | 1662 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2017 | 317 | 0.120 |
Why?
|
| Body Weight | 1 | 2016 | 452 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 31 | 0.120 |
Why?
|
| Drug Tolerance | 1 | 2014 | 64 | 0.120 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2014 | 9 | 0.120 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 28 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 2004 | 24 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 579 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2014 | 102 | 0.120 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 1012 | 0.110 |
Why?
|
| Mice, Inbred C3H | 3 | 2012 | 371 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 153 | 0.110 |
Why?
|
| Antigens | 1 | 2014 | 229 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2012 | 6 | 0.110 |
Why?
|
| Heart | 1 | 2016 | 573 | 0.110 |
Why?
|
| Cross-Priming | 1 | 2012 | 48 | 0.100 |
Why?
|
| B-Cell CLL-Lymphoma 10 Protein | 2 | 2009 | 8 | 0.100 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 645 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 85 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2024 | 76 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 836 | 0.100 |
Why?
|
| beta Catenin | 1 | 2014 | 266 | 0.100 |
Why?
|
| Time Factors | 5 | 2019 | 5320 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1650 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 1157 | 0.100 |
Why?
|
| Multiprotein Complexes | 2 | 2009 | 96 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 1063 | 0.100 |
Why?
|
| Genetic Loci | 1 | 2012 | 253 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 2399 | 0.090 |
Why?
|
| Colitis | 1 | 2014 | 244 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2006 | 137 | 0.090 |
Why?
|
| Microbiota | 1 | 2016 | 398 | 0.090 |
Why?
|
| Colon | 1 | 2014 | 509 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 33 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2552 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 594 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2011 | 162 | 0.090 |
Why?
|
| Peptides | 2 | 2011 | 646 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2009 | 196 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 2001 | 0.090 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2012 | 241 | 0.090 |
Why?
|
| Chromatin | 1 | 2012 | 397 | 0.090 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2009 | 6 | 0.090 |
Why?
|
| Phenotype | 1 | 2016 | 2439 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 805 | 0.080 |
Why?
|
| Young Adult | 5 | 2021 | 6288 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 573 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2009 | 49 | 0.080 |
Why?
|
| I-kappa B Proteins | 1 | 2009 | 54 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 321 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 245 | 0.080 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 29 | 0.080 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 42 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2008 | 10 | 0.080 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 51 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 36 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 1488 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2011 | 794 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 269 | 0.080 |
Why?
|
| Epidermis | 1 | 2007 | 102 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 184 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 3000 | 0.070 |
Why?
|
| Lung Transplantation | 1 | 2010 | 290 | 0.070 |
Why?
|
| Adolescent | 4 | 2021 | 9237 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2021 | 1533 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 340 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2019 | 9003 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 66 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 92 | 0.070 |
Why?
|
| Stem Cells | 1 | 2008 | 372 | 0.070 |
Why?
|
| Glioma | 1 | 2008 | 293 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 226 | 0.060 |
Why?
|
| Butadienes | 1 | 2004 | 34 | 0.060 |
Why?
|
| Mutation | 3 | 2023 | 4132 | 0.060 |
Why?
|
| Streptococcus pyogenes | 1 | 2004 | 35 | 0.060 |
Why?
|
| Superantigens | 1 | 2004 | 24 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2012 | 1652 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2004 | 100 | 0.060 |
Why?
|
| Nitriles | 1 | 2004 | 160 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2362 | 0.060 |
Why?
|
| Imidazoles | 1 | 2004 | 148 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2011 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 2863 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 207 | 0.060 |
Why?
|
| Sirolimus | 1 | 2004 | 170 | 0.060 |
Why?
|
| Calcineurin | 1 | 2003 | 20 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2014 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 204 | 0.050 |
Why?
|
| Gene Expression | 3 | 2016 | 1310 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 181 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 102 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2004 | 275 | 0.050 |
Why?
|
| DNA Probes | 1 | 2002 | 77 | 0.050 |
Why?
|
| Pyridines | 1 | 2004 | 315 | 0.050 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 60 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 44 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2023 | 138 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 192 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 373 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2020 | 4 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 887 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2020 | 30 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 291 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2021 | 71 | 0.050 |
Why?
|
| A549 Cells | 1 | 2020 | 41 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 87 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2002 | 229 | 0.050 |
Why?
|
| Taxoids | 1 | 2021 | 130 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 33 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 112 | 0.050 |
Why?
|
| Epigenomics | 1 | 2021 | 103 | 0.050 |
Why?
|
| Carboplatin | 1 | 2021 | 304 | 0.040 |
Why?
|
| Binding Sites | 2 | 2014 | 1117 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 293 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 299 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 29 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2020 | 298 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 170 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 272 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 699 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1182 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 174 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 9 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 11 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 26 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 96 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2011 | 73 | 0.040 |
Why?
|
| Fever | 1 | 2019 | 128 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 57 | 0.040 |
Why?
|
| Protein Kinase C-theta | 2 | 2008 | 16 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 179 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2011 | 277 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 55 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 321 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 319 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 434 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 170 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 393 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 576 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 156 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1763 | 0.040 |
Why?
|
| CD40 Ligand | 2 | 2008 | 69 | 0.040 |
Why?
|
| Genomics | 1 | 2023 | 761 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 506 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 435 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 37 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 78 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 271 | 0.030 |
Why?
|
| Transfection | 2 | 2011 | 911 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2008 | 466 | 0.030 |
Why?
|
| United States | 2 | 2019 | 6955 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 102 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 141 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 164 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 169 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 635 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1889 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 181 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 204 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 848 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 308 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 628 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1214 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 620 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2014 | 163 | 0.030 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Genes, APC | 1 | 2014 | 27 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2014 | 80 | 0.030 |
Why?
|
| Sulfasalazine | 2 | 2004 | 34 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2014 | 76 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 543 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 374 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1837 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 282 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 97 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 682 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2016 | 275 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 463 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 901 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2004 | 511 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 1097 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 754 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 447 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 136 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 65 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 786 | 0.020 |
Why?
|
| Protein Binding | 2 | 2004 | 1487 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2752 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 134 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2008 | 73 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 54 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 33 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 781 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2008 | 139 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 54 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1241 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2008 | 144 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 397 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 257 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 234 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2008 | 198 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 267 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 2006 | 46 | 0.020 |
Why?
|
| Ionomycin | 1 | 2006 | 21 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 698 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 814 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 20 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 32 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2006 | 37 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2006 | 48 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1715 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 135 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2006 | 268 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 166 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 147 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2008 | 423 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 956 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2004 | 42 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2006 | 213 | 0.020 |
Why?
|
| Dimerization | 1 | 2004 | 143 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 556 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 273 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2004 | 135 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 299 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 646 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 12 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 519 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 2002 | 21 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2002 | 24 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2002 | 23 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 49 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2062 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1296 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3027 | 0.010 |
Why?
|